Off-the-shelf tumor cell vaccine tailored to your tumor’s HLA type for advanced prostate cancer

Who could benefit from this research

What this research studies

This grant funds development of a personalized cancer vaccine made from whole tumor cells that are selected to match a patient’s HLA alleles, with the aim of provoking a strong, targeted immune response against the cancer. The approach combines two actions: presenting cancer antigens to immune cells and directly activating immune cells to attack the tumor. The program builds on prior work with a first-generation product and seeks to advance manufacturing and clinical testing in a way that could improve survival for men with metastatic prostate cancer. Participation may involve tumor sample analysis, immune monitoring, and potential future trial enrollment. The project is led by BriaCell Therapeutics and collaborators at a Philadelphia institution, focusing on translating a novel, allogeneic/partially-autologous vaccine approach toward patients who could benefit from improved tumor control.

Why it matters

Where this research is happening

• Briacell Therapeutics Corp
  Philadelphia, United States Active

Researchers

• Principal investigator: Williams, William Valentine — Briacell Therapeutics Corp
• Study coordinator: Williams, William Valentine

Related research

Other NIH-funded projects on the same topics.

• Combination immunotherapy with radioligand therapy for metastatic prostate cancer

  A study aims to help men with advanced prostate cancer by combining immune therapy with targeted radiation to boost the body’s own defense against cancer.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11415135

• Understanding what drives lethal metastatic prostate cancer in men

  This grant looks at why some prostate cancers become deadly and spread, using patient-derived cells and mouse models.

  NIH research University of Nebraska Medical Center · Omaha, United States · NIH-11411456

• ASH1L’s role in metastatic prostate cancer and its immune environment

  Aims to understand how the ASH1L gene helps prostate cancer spread and how it shapes the immune environment in bone metastases so future therapies can target this process.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11396556

• Molecular drivers of lineage changes and new therapies for metastatic prostate cancer

  A multi-year study at a major university will explore how metastatic prostate cancer changes its cell type and how to target those changes to help patients.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11389345

• How gut bacteria may affect prostate cancer therapy and resistance

  A new study looks at how gut bacteria make compounds that influence prostate cancer treatments and may drive resistance to therapy.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11361092

• Blood test to detect resistance to hormone therapy in advanced prostate cancer

  This project tests a new blood-based DNA test to spot early resistance to androgen (hormone) therapies in men with advanced prostate cancer.

  NIH research Washington University · Saint Louis, United States · NIH-11231709

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.